Tempus AI announced a new research partnership with the Institute for Follicular Lymphoma Innovation (IFLI) that will generate the first multi‑omic dataset for follicular lymphoma. The study will collect next‑generation sequencing, proteomics, and DNA‑methylation data from patients, creating a comprehensive resource that can accelerate biomarker discovery and precision‑medicine research for the disease, which accounts for 10‑20% of all non‑Hodgkin lymphoma cases in the United States.
Follicular lymphoma is an indolent form of lymphoma that often progresses within two years of initial therapy for about 20% of patients, and its five‑year overall survival remains around 50%. By integrating genomic, proteomic, and epigenomic data, the partnership aims to uncover the biological drivers of the disease and identify new therapeutic targets that can be translated into targeted therapies. The dataset will also feed into Tempus’s AI platform, enabling more accurate predictive models and actionable insights for clinicians worldwide.
The collaboration expands Tempus’s already‑large multimodal data library and strengthens its AI‑driven oncology platform, positioning the company as a leader in lymphoma research. It also opens the door to future drug‑development partnerships, reinforcing the firm’s competitive moat in precision medicine. The study builds on an existing IFLI partnership that has already created a real‑world follicular lymphoma data library, making this the first formal research study between the two organizations.
"This collaboration with IFLI signifies our shared commitment to generating rich, multimodal datasets that can help transform research for this specific patient population," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "The comprehensive approach will provide researchers with a uniquely deep and actionable understanding of follicular lymphoma, paving the way for new discoveries and personalized treatment strategies."
"Tempus was selected for its unmatched capabilities in molecular profiling and data science, and we’re confident they are uniquely positioned to deliver on our shared vision," said David McCullagh, Managing Director of IFLI. "Together, we aim to create a transformative dataset that integrates real‑world clinical insights with advanced testing and analytics to uncover the biological drivers of FL and enable more personalized therapies that improve patient outcomes globally."
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.